Compare BioNTech SE - ADR (BNTX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Ryanair Holdings plc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Ryanair Holdings plc trades at $64.3 (market cap $31.19B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.54% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | RYAAY | |
|---|---|---|
Market Cap | $22.86B | $31.19B |
Sector | Health | Industrials |
52-Week High | $119.34 | $73.82 |
52-Week Low | $83.89 | $53.24 |
Enterprise Value | $6.53B | $28.85B |
Dividend Yield | — | 1.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
RYAAY trades at $63.91, down 1.14% today, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 13.98% net income margin and 25.37% ROE, supported by consistent earnings beats in recent quarters. Recent news includes a window incident investigation and CEO contract extension, while passenger traffic grew 7% year-over-year in June 2026 (Zacks Investment Research, 2026-07-02).
The outlook remains positive with analyst consensus at 62.5% buy ratings, though risks include rising fuel costs and regulatory scrutiny. Valuation appears reasonable with a P/E of 13.74 and EV/EBITDA of 6.57, suggesting potential upside if travel demand sustains. Near-term focus is on Q2 2026 earnings against expectations of $1.37 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
